Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study

BACKGROUND AND OBJECTIVES: Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2) Day 1, 5-FU 2400 mg/m(2) × 48 h IV, peg-filgrastim 6 mg SQ day 3, every 14 days) has subst...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Surg Oncol
Egile Nagusiak: de Marsh, Robert W., Talamonti, Mark S., Baker, Marshall S., Posner, Mitchell, Roggin, Kevin, Matthews, Jeffrey, Catenacci, Daniel, Kozloff, Mark, Polite, Blase, Britto, Michele, Wang, Chi, Kindler, Hedy
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890423/
https://ncbi.nlm.nih.gov/pubmed/29044544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jso.24872
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak